Клиническая фармакогенетика блокаторов рецепторов ангиотензина II: новые возможности индивидуализации фармакотерапии?

Обзор посвящен перспективам применения фармакогенетических исследований блокаторов рецептора ангиотензина II (БРА) в клинической практике. Рассмотрены результаты исследований влияния полиморфизма генов системы биотрансформации (CYP2C9) и ренин-ангиотензин-альдостероновой системы на фармакокинетику и фармакодинамику БРА. Рассматриваемые фармакогенетические исследования были выполнены не только у здоровых добровольцев, но и у больных артериальной гипертензией и хронической сердечной недостаточностью. 

1. Кукес В.Г. Метаболизм лекарственных средств: клиникофармакологические аспекты. Москва «Реафарм» 2004; 18- 27, 40-7.

2. Лильин Е.Т., Богомазов Е.А., Гофман-Кадошников П.Б. Генетика для врача. Москва «Медицина» 1990; 176-87.

3. Середенин С.Б. Лекции по фармакогенетике. Москва «МИА» 2004; 303 с.

4. Соради И. Основы и педиатрические аспекты фармакогенетики. Будапешт. Изд-во Академии наук Венгрии 1984; 248 с.

5. Сычев Д.А. Клиническая фармакогенетика. Клиническая фармакология под ред. Академика РАМН, проф. Кукеса В.Г. Москва «ГЕОТАР-МЕД» 2004.

6. Allabi AC, Gala JL, Horsmans Y, et al. Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans. Clin Pharmacol Ther 2004; 76(2): 113-8.

7. Arnett DK, Davis BR, Ford CE, et al. Pharmacogenetic association of the angiotensin-converting enzyme insertion/ deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study. Circulation 2005; 111(25): 3374-83. Epub 2005 Jun 20.

8. Babaoglu MO, Yasar U, Sandberg M, et al. CYP2C9 genetic variants and losartan oxidation in a Turkish population. Eur J Clin Pharmacol 2004; 60(5): 337-42. Epub 2004 Jun 10.

9. Conrady AO, Kiselev IO, Usachev NI, et al. Effect of 24- week treatment with telmisartan on myocardial structure and function: relationship to insertion/deletion polymorphism of the angiotensin-converting enzyme gene. J Int Med Res 2005; 33(Suppl 1): 30A-8.

10. Hallberg P, Karlsson J, Kurland L, et al. The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. J Hypertens 2002; 20(10): 2089-93.

11. Heller S, Linhart A, Jindra A, et al. Association of -344/T/ C aldosterone synthase polymorphism (CYP11B2) with left ventricular structure and humoral parameters in young normotensive men. Blood Press 2004; 13(3): 158-63.

12. Hong X, Zhang S, Mao G, et al. CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population. Eur J Clin Pharmacol 2005; 61(9): 627-34.

13. Rodgers JE, Patterson JH. Angiotensin II-Receptor Blockers: Clinical Relevance and Therapeutic Role. Am J Health-Syst Pharm 2001; 58(8): 671-83.

14. Kurland L, Melhus H, Karlsson J, et al. Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. Am J Hypertens 2002; 15(5): 389-93.

15. Kurland L, Liljedahl U, Karlsson J, et al. Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. AJH 2004; 17: 8-13.

16. Kurland L, Melhus H, Karlsson J, et al. Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. J Hypertens 2002; 20(4): 657-63.

17. Kurland L, Melhus H, Karlsson J, et al. Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. J Hypertens 2001; 19(10): 1783-7.

18. Lee CR, Pieper JA, Hinderliter AL, et al. Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals. Pharmacotherapy 2003; 23(6): 720-5.

19. Ortlepp JR, Hanrath P, Mevissen V, et al. Variants of the CYP11B2 gene predict response to therapy with candesartan. Eur J Pharmacol 2002; 445(1-2): 151-2.

20. Pharmacogenomics/ edited by Rothstein M.A. Willy-liss. New Jersey 2003; 368 p.

21. Redon J, Luque-Otero M, Martell N, Chaves FJ; POLPRI Investigators. Renin-angiotensin system gene polymorphisms: relationship with blood pressure and microalbuminuria in telmisartan-treated hypertensive patients. Pharmacogenomics J 2005; 5(1): 14-20.

22. Sekino K, Kubota T, Okada Y, et al. Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects. Eur J Clin Pharmacol 2003; 59(8-9): 589-92.

23. Sookoian S, Castano G, Garcia SI, et al. A1166C angiotensin II type 1 receptor gene polymorphism may predict hemodynamic response to losartan in patients with cirrhosis and portal hypertension. Am J Gastroenterol 2005; 100(3): 636-42.

24. Spiering W, Kroon AA, Fuss-Lejeune MJ, de Leeuw PW. Genetic contribution to the acute effects of angiotensin II type 1 receptor blockade. J Hypertens 2005; 23(4): 753-8.

25. Yasar U, Eliasson E, Forslund-Bergengren C, et al. The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro. Eur J Clin Pharmacol 2001; 57(10): 729-35.

26. Yasar U, Forslund-Bergengren C, Tybring G, et al. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Рharmacol Ther 2002; 71: 89-98.

27. Weekers L, Bouhanick B, Hadjadj S, et al. Modulation of the Renal Response to ACE Inhibition by ACE Insertion/Deletion Polymorphism During Hyperglycemia in Normotensive, Normoalbuminuric Type 1 Diabetic Patients. Diabetes 2005; 54(10): 2961-7.